1. Pink Sheet
  2. >>Legal & IP

Bye, Bye Byetta: Teva To Take AstraZeneca's GLP-1 Agonist Generic Two Years Early

 
• By Brenda Sandburg

First in class is the first to fall, and Byetta could go even earlier than the October 2017 date set in Teva settlement since AstraZeneca still faces a generic challenge from Amneal – and a direct attack on its patents from Sanofi.

Teva Pharmaceutical Industries Ltd.'s patent infringement settlement with AstraZeneca PLC allows it to launch a generic version of Byetta (exenatide) in the U.S. two years and three months before expiration of the last patent covering the GLP-1 agonist.

Teva announced in a June 23 release that it had settled litigation relating to seven AstraZeneca patents covering the diabetes...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico

 
• By Francesca Bruce

Legal experts warn, however, that new Mexican procurement rules are discriminatory and could be challenged in the courts.

EU CHMP Opinions And MAA Updates

 
• By Neena Brizmohun

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy

 
• By Michael McCaughan

The Trump Administration’s rhetoric and policy approaches illustrate the confusion that often arises between efforts to cut drug prices and cutting spending.